People with diabetes who need to track both glucose and ketone levels have long juggled separate devices, pricking their fingers for blood-ketone readings while wearing a continuous glucose monitor on their arm. Abbott changed that equation by securing a CE Mark for its Libre Duo system, the first wearable to measure glucose and beta-hydroxybutyrate from a single sensor worn on the body. The device uses two neighboring electrodes with distinct enzyme chemistries on one patch, and peer-reviewed feasibility data show reliable ketone readings across a 14-day wear period. Whether that convenience translates into higher ketone-monitoring rates and fewer diabetic ketoacidosis emergencies is the question that matters most.
Why dual glucose-ketone sensing matters right now
Diabetic ketoacidosis, or DKA, remains one of the most dangerous acute complications of diabetes. Catching rising ketone levels early can prevent hospital visits, yet surveys published in the Journal of Diabetes Science and Technology show that many patients still rely on urine-based checks or forgo ketone testing. Blood-ketone meters are more accurate than urine strips, but they require a separate fingerstick, extra test strips, and the motivation to test at the right moment. That friction keeps testing rates low, especially overnight or during illness when ketone spikes are most likely.
A dual sensor changes the math by removing the extra step. If glucose and ketone data flow from one device, the hypothesis is straightforward: users will generate far more ketone readings per day than they would with a standalone meter. That claim is testable. De-identified device logs from early adopters could show, within six months of a commercial launch, whether daily ketone data density rises compared to the baseline of occasional fingerstick checks. Higher data density alone does not prove better outcomes, but it is the necessary first condition for earlier DKA detection.
Continuous ketone data could also reshape how clinicians counsel high-risk groups. People with a history of DKA, those starting on SGLT2 inhibitors, and children with type 1 diabetes may benefit from earlier alerts when ketones begin to climb. Today, many of those patients are told to check ketones only when they feel unwell or see high glucose readings. A dual sensor could nudge practice patterns toward proactive monitoring: instead of waiting for symptoms, clinicians might review ketone trends at every visit, just as they now review time-in-range for glucose.
Feasibility data and the sensor design behind Abbott’s Libre Duo
The technical foundation rests on two published studies. A first-in-human feasibility trial demonstrated that a subcutaneous ketone sensor could measure beta-hydroxybutyrate in interstitial fluid over a 14-day wear period. That study, led by Shridhara Alva and colleagues, was later identified by the 2021 Continuous Ketone Monitoring Consensus Report as a key breakthrough in proving that ketones could be tracked continuously through a wearable platform. The consensus document, hosted on PubMed Central, noted that low adherence with existing ketone-testing methods left a gap that continuous sensing could fill.
Building on that work, a subsequent peer-reviewed paper in Diabetes Technology and Therapeutics described the dual glucose-ketone architecture in detail. The design places two electrodes side by side on a single filament, each coated with a different enzyme layer. One electrode responds to glucose; the other responds to beta-hydroxybutyrate. Both use amperometric detection, and the system targets factory calibration so users do not need to perform manual calibration steps. Factory calibration is a practical requirement for consumer adoption because it eliminates the fingerstick routine that earlier continuous monitors demanded.
Abbott received a CE Mark for the Libre Duo and Libre Duo 10 Day variants, making the system available in markets that accept CE-marked devices. In the United States, the FDA’s Breakthrough Devices Program offers an expedited interaction and review pathway for technologies that treat or diagnose life-threatening conditions. That designation, as the FDA itself explains, does not equal proof of safety, effectiveness, or regulatory clearance. It simply means the agency will work more closely with the manufacturer during the review process.
Gaps between a CE Mark and real-world ketone monitoring gains
Several open questions separate the published feasibility work from proof that dual sensing will reduce DKA events. The 14-day feasibility study confirmed that continuous ketone readings are technically possible, but it did not report clinical outcomes such as hospitalization rates or time-to-treatment for rising ketones. No published trial has yet compared DKA incidence in a group using a dual sensor against a matched group using standard glucose CGM plus a blood-ketone meter.
Calibration stability is another unknown. Factory calibration must hold accurate across the full wear period, through sweat, movement, and varying tissue conditions. The published sensor-design paper describes the calibration approach, but long-term drift data and interference studies beyond the initial 14-day window have not appeared in the peer-reviewed record. Sensor accuracy at the low end of the ketone range, where early warning matters most, will need validation in larger and more diverse populations before clinicians can rely on it for treatment decisions.
There are also behavioral and workflow questions. For clinicians, adding a second continuous analyte to review could increase visit complexity. Electronic health record systems and diabetes data platforms will need to decide how to visualize ketone trends alongside glucose traces without overwhelming users. For patients, the value proposition has to be clear: if alerts for rising ketones are frequent but not actionable, alarm fatigue could erode trust in the system.
Regulatory timelines add uncertainty for U.S. users. FDA device-review records show multiple recent submissions in the continuous-monitoring category, but the Breakthrough Devices designation alone does not predict when or whether a clearance decision will arrive. Readers in CE Mark jurisdictions may see the Libre Duo sooner, while those in the United States will need to wait for a separate FDA decision.
The practical next step: from feasibility to outcomes
The path from promising feasibility data to routine use will run through carefully designed outcomes studies. The most informative trials would randomize high-risk patients to either dual sensing or standard CGM plus access to a blood-ketone meter, then track DKA events, emergency visits, and time to intervention over at least a year. Subgroup analyses could explore whether benefits concentrate in specific populations, such as adolescents, people using insulin pumps, or those on SGLT2 inhibitors.
In parallel, real-world evidence from early adopters in CE Mark regions can help answer basic usage questions. How often do users review ketone data compared with glucose data? Do clinicians adjust insulin doses, sick-day rules, or hospitalization thresholds based on continuous ketone trends? Are there patterns of false alarms or missed events that suggest the need for algorithm refinements?
Health systems and payers will watch those data closely. If dual sensing can demonstrate fewer DKA admissions or shorter hospital stays, the economic argument for reimbursement becomes stronger. Conversely, if usage is sporadic or alerts rarely change management, payers may view dual sensing as a convenience feature rather than a safety tool.
For now, Libre Duo’s CE Mark is best understood as a technical milestone rather than a settled clinical solution. The device shows that dual glucose-ketone sensing is feasible in a wearable format and that factory-calibrated ketone readings can be delivered over a typical sensor life. The harder work still lies ahead: proving that this new stream of data changes decisions in time to prevent crises, and doing so in a way that fits into the daily realities of people living with diabetes and the clinicians who care for them.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
